Johnson & Johnson (JNJ) · Insider trading
What Johnson & Johnson's directors, officers and largest holders bought and sold themselves, from the Form 4 each of them files with the SEC within two business days of a trade. Open-market purchases and sales first: those are the trades somebody chose to make at the market price.
Bought, 12 months
$257,688
1 insider, 1 trade
Sold, 12 months
$150.67M
10 insiders, 0% under a plan
Net, 12 months
−$150.41M
bought less sold
Latest filing
2026-09-04
filings read to 2026-10-19
Who traded, two years
| Insider | Bought | Sold | Trades | Last trade | Holds after |
|---|---|---|---|---|---|
| Duato JoaquinDirector, CEO and Chairman of the Board | – | $89.39M | 7 | 2026-08-13 | 378,282 |
| Wolk Joseph JExec VP, CFO | – | $26.75M | 6 | 2026-02-17 | 38,961 |
| Reed John CEVP, Innovative Medicine, R&D | – | $20.42M | 5 | 2026-02-17 | 12,941 |
| Schmid TimothyEVP, WW Chair, MedTech | – | $15.15M | 6 | 2026-09-02 | 25,447 |
| Swanson James D.EVP, CIO | – | $15.11M | 3 | 2026-02-17 | 25,698 |
| Taubert Jennifer LEVP, WWC. Innovative Medicine | – | $13.99M | 2 | 2026-08-17 | 194,451 |
| Broadhurst VanessaEVP, Global Corp Affairs | – | $7.30M | 2 | 2026-07-20 | 23,003 |
| Forminard ElizabethEVP, Chief Legal Officer | – | $4.09M | 2 | 2026-08-06 | 23,568 |
| Wengel Kathryn EEVP, Chief TO and Risk Officer | – | $2.41M | 1 | 2026-06-11 | 114,288 |
| Decker Robert JVP Corporate Controller | – | $2.17M | 2 | 2026-02-27 | 23,682 |
| Morikis John GDirector | $257,688 | – | 1 | 2025-11-26 | 1,849 |
| Weinberger Mark ADirector | $147,220 | – | 1 | 2024-12-12 | 1,000 |
Open-market purchases and sales
Newest first. “Plan” marks a trade made under a 10b5-1 plan set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Holds after | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-02 | Schmid TimothyEVP, WW Chair, MedTech | Sale | 11,070 | 274.74 | $3.04M | 25,447 | Form 4 |
| 2026-09-02 | Schmid TimothyEVP, WW Chair, MedTech | Sale | 22,527 | 274.74 | $6.19M | 25,447 | Form 4 |
| 2026-08-17 | Taubert Jennifer LEVP, WWC. Innovative Medicine | Sale | 15,000 | 263.36 | $3.95M | 194,451 | Form 4 |
| 2026-08-13 | Duato JoaquinDirector, CEO and Chairman of the Board | Sale | 20,976 | 262.00 | $5.50M | 378,282 | Form 4 |
| 2026-08-13 | Duato JoaquinDirector, CEO and Chairman of the Board | Sale | 102,315 | 261.00 | $26.70M | 275,967 | Form 4 |
| 2026-08-06 | Forminard ElizabethEVP, Chief Legal Officer | Sale | 9,344 | 257.76 | $2.41M | 23,568 | Form 4 |
| 2026-08-06 | Forminard ElizabethEVP, Chief Legal Officer | Sale | 6,574 | 255.93 | $1.68M | 16,994 | Form 4 |
| 2026-08-05 | Duato JoaquinDirector, CEO and Chairman of the Board | Sale | 41,957 | 258.06 | $10.83M | 282,490 | Form 4 |
| 2026-08-05 | Duato JoaquinDirector, CEO and Chairman of the Board | Sale | 6,523 | 258.74 | $1.69M | 275,967 | Form 4 |
| 2026-07-20 | Broadhurst VanessaEVP, Global Corp Affairs | Sale | 23,054 | 251.27 | $5.79M | 23,003 | Form 4 |
| 2026-06-11 | Wengel Kathryn EEVP, Chief TO and Risk Officer | Sale | 10,000 | 241.15 | $2.41M | 114,288 | Form 4 |
| 2026-02-27 | Decker Robert JVP Corporate Controller | Sale | 4,075 | 247.87 | $1.01M | 23,682 | Form 4 |
| 2026-02-20 | Schmid TimothyEVP, WW Chair, MedTech | Sale | 1,322 | 245.66 | $324,763 | 25,447 | Form 4 |
| 2026-02-18 | Schmid TimothyEVP, WW Chair, MedTech | Sale | 13,625 | 244.20 | $3.33M | 26,769 | Form 4 |
| 2026-02-18 | Schmid TimothyEVP, WW Chair, MedTech | Sale | 8,998 | 244.53 | $2.20M | 26,769 | Form 4 |
| 2026-02-17 | Broadhurst VanessaEVP, Global Corp Affairs | Sale | 6,197 | 243.39 | $1.51M | 23,003 | Form 4 |
| 2026-02-17 | Reed John CEVP, Innovative Medicine, R&D | Sale | 21,721 | 243.00 | $5.28M | 12,941 | Form 4 |
| 2026-02-17 | Reed John CEVP, Innovative Medicine, R&D | Sale | 29,927 | 243.00 | $7.27M | 12,941 | Form 4 |
| 2026-02-17 | Reed John CEVP, Innovative Medicine, R&D | Sale | 2,283 | 243.00 | $554,769 | 10,658 | Form 4 |
| 2026-02-17 | Wolk Joseph JExec VP, CFO | Sale | 19,241 | 242.99 | $4.68M | 38,961 | Form 4 |
| 2026-02-17 | Wolk Joseph JExec VP, CFO | Sale | 12,066 | 242.87 | $2.93M | 38,961 | Form 4 |
| 2026-02-17 | Wolk Joseph JExec VP, CFO | Sale | 33,386 | 242.75 | $8.10M | 38,961 | Form 4 |
| 2026-02-17 | Wolk Joseph JExec VP, CFO | Sale | 24,961 | 242.68 | $6.06M | 14,000 | Form 4 |
| 2026-02-17 | Swanson James D.EVP, CIO | Sale | 20,521 | 242.70 | $4.98M | 25,698 | Form 4 |
| 2026-02-13 | Swanson James D.EVP, CIO | Sale | 19,368 | 243.76 | $4.72M | 25,020 | Form 4 |
| 2026-02-13 | Swanson James D.EVP, CIO | Sale | 22,191 | 243.71 | $5.41M | 25,020 | Form 4 |
| 2026-01-26 | Duato JoaquinDirector, CEO and Chairman of the Board | Saleindirect | 51,218 | 220.99 | $11.32M | 79,634 | Form 4 |
| 2026-01-26 | Duato JoaquinDirector, CEO and Chairman of the Board | Saleindirect | 48,782 | 221.48 | $10.80M | 30,852 | Form 4 |
| 2025-11-26 | Morikis John GDirector | Buy | 1,250 | 206.15 | $257,688 | 1,849 | Form 4 |
| 2025-10-17 | Reed John CEVP, Innovative Medicine, R&D | Sale | 21,721 | 192.71 | $4.19M | 10,658 | Form 4 |
| 2025-09-04 | Taubert Jennifer LEVP, WWC. Innovative Medicine | Sale | 56,471 | 177.81 | $10.04M | 178,013 | Form 4 |
| 2025-08-22 | Duato JoaquinDirector, CEO and Chairman of the Board | Sale | 125,824 | 179.21 | $22.55M | 275,967 | Form 4 |
| 2025-08-15 | Wolk Joseph JExec VP, CFO | Sale | 16,820 | 176.91 | $2.98M | 14,000 | Form 4 |
| 2025-07-17 | Reed John CEVP, Innovative Medicine, R&D | Sale | 19,137 | 163.55 | $3.13M | 10,658 | Form 4 |
| 2025-02-25 | Decker Robert JVP Corporate Controller | Sale | 6,999 | 165.88 | $1.16M | 21,001 | Form 4 |
| 2025-02-18 | Schmid TimothyEVP, WW Chair, MedTech | Sale | 403 | 156.15 | $62,928 | 15,098 | Form 4 |
| 2025-02-07 | Wolk Joseph JExec VP, CFO | Sale | 13,015 | 153.89 | $2.00M | 0 | Form 4 |
| 2024-12-12 | Weinberger Mark ADirector | Buy | 1,000 | 147.22 | $147,220 | 1,000 | Form 4 |
Grants, exercises and other transactions
Pay, tax and paperwork rather than a choice to trade at the market price. Two years.
118 × option exercise92 × shares withheld for tax2 × gift
Show them
| Date | Insider | What | Shares | Price | Holds after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-02 | Schmid TimothyEVP, WW Chair, MedTech | Option exercise M | +11,070 | 131.94 | 36,517 | Form 4 |
| 2026-09-02 | Schmid TimothyEVP, WW Chair, MedTech | Option exercise M | +22,527 | 151.41 | 47,974 | Form 4 |
| 2026-08-17 | Taubert Jennifer LEVP, WWC. Innovative Medicine | Option exercise M | +15,000 | 115.67 | 209,451 | Form 4 |
| 2026-08-13 | Duato JoaquinDirector, CEO and Chairman of the Board | Option exercise M | +123,291 | 115.67 | 399,258 | Form 4 |
| 2026-08-06 | Forminard ElizabethEVP, Chief Legal Officer | Option exercise M | +9,344 | 131.94 | 32,912 | Form 4 |
| 2026-07-20 | Broadhurst VanessaEVP, Global Corp Affairs | Option exercise M | +11,129 | 129.51 | 34,132 | Form 4 |
| 2026-07-20 | Broadhurst VanessaEVP, Global Corp Affairs | Option exercise M | +11,925 | 131.94 | 46,057 | Form 4 |
| 2026-06-11 | Wengel Kathryn EEVP, Chief TO and Risk Officer | Option exercise M | +10,000 | 115.67 | 124,288 | Form 4 |
| 2026-05-01 | Reed John CEVP, Innovative Medicine, R&D | Option exercise M | +25,255 | – | 35,913 | Form 4 |
| 2026-05-01 | Reed John CEVP, Innovative Medicine, R&D | Shares withheld for tax F | −11,002 | 229.85 | 24,911 | Form 4 |
| 2026-02-27 | Decker Robert JVP Corporate Controller | Option exercise M | +4,075 | 115.67 | 27,757 | Form 4 |
| 2026-02-18 | Schmid TimothyEVP, WW Chair, MedTech | Option exercise M | +13,625 | 115.67 | 40,394 | Form 4 |
| 2026-02-18 | Schmid TimothyEVP, WW Chair, MedTech | Option exercise M | +8,998 | 129.51 | 35,767 | Form 4 |
| 2026-02-17 | Reed John CEVP, Innovative Medicine, R&D | Option exercise M | +21,721 | 157.92 | 34,662 | Form 4 |
| 2026-02-17 | Reed John CEVP, Innovative Medicine, R&D | Option exercise M | +29,927 | 156.15 | 42,868 | Form 4 |
| 2026-02-17 | Wolk Joseph JExec VP, CFO | Option exercise M | +19,241 | 115.67 | 58,202 | Form 4 |
| 2026-02-17 | Wolk Joseph JExec VP, CFO | Option exercise M | +12,066 | 129.51 | 51,027 | Form 4 |
| 2026-02-17 | Wolk Joseph JExec VP, CFO | Option exercise M | +33,386 | 131.94 | 72,347 | Form 4 |
| 2026-02-17 | Swanson James D.EVP, CIO | Option exercise M | +20,521 | 164.62 | 46,219 | Form 4 |
| 2026-02-15 | Broadhurst VanessaEVP, Global Corp Affairs | Option exercise M | +492 | – | 29,196 | Form 4 |
| 2026-02-15 | Broadhurst VanessaEVP, Global Corp Affairs | Shares withheld for tax F | −252 | 243.45 | 28,944 | Form 4 |
| 2026-02-15 | Broadhurst VanessaEVP, Global Corp Affairs | Option exercise M | +526 | – | 29,470 | Form 4 |
| 2026-02-15 | Broadhurst VanessaEVP, Global Corp Affairs | Shares withheld for tax F | −270 | 243.45 | 29,200 | Form 4 |
| 2026-02-15 | Duato JoaquinDirector, CEO and Chairman of the Board | Option exercise M | +3,682 | – | 323,504 | Form 4 |
| 2026-02-15 | Duato JoaquinDirector, CEO and Chairman of the Board | Shares withheld for tax F | −1,602 | 243.45 | 321,902 | Form 4 |
| 2026-02-15 | Duato JoaquinDirector, CEO and Chairman of the Board | Option exercise M | +4,505 | – | 326,407 | Form 4 |
| 2026-02-15 | Duato JoaquinDirector, CEO and Chairman of the Board | Shares withheld for tax F | −1,960 | 243.45 | 324,447 | Form 4 |
| 2026-02-15 | Schmid TimothyEVP, WW Chair, MedTech | Option exercise M | +1,028 | – | 26,206 | Form 4 |
| 2026-02-15 | Schmid TimothyEVP, WW Chair, MedTech | Shares withheld for tax F | −15 | 243.45 | 26,191 | Form 4 |
| 2026-02-15 | Schmid TimothyEVP, WW Chair, MedTech | Option exercise M | +1,026 | – | 27,217 | Form 4 |
| 2026-02-15 | Schmid TimothyEVP, WW Chair, MedTech | Shares withheld for tax F | −448 | 243.45 | 26,769 | Form 4 |
| 2026-02-15 | Taubert Jennifer LEVP, WWC. Innovative Medicine | Option exercise M | +1,594 | – | 194,365 | Form 4 |
| 2026-02-15 | Taubert Jennifer LEVP, WWC. Innovative Medicine | Shares withheld for tax F | −816 | 243.45 | 193,549 | Form 4 |
| 2026-02-15 | Taubert Jennifer LEVP, WWC. Innovative Medicine | Option exercise M | +1,847 | – | 195,396 | Form 4 |
| 2026-02-15 | Taubert Jennifer LEVP, WWC. Innovative Medicine | Shares withheld for tax F | −945 | 243.45 | 194,451 | Form 4 |
| 2026-02-15 | Forminard ElizabethEVP, Chief Legal Officer | Option exercise M | +961 | – | 23,541 | Form 4 |
| 2026-02-15 | Forminard ElizabethEVP, Chief Legal Officer | Shares withheld for tax F | −492 | 243.45 | 23,049 | Form 4 |
| 2026-02-15 | Forminard ElizabethEVP, Chief Legal Officer | Option exercise M | +1,063 | – | 24,112 | Form 4 |
| 2026-02-15 | Forminard ElizabethEVP, Chief Legal Officer | Shares withheld for tax F | −544 | 243.45 | 23,568 | Form 4 |
| 2026-02-15 | Reed John CEVP, Innovative Medicine, R&D | Option exercise M | +1,349 | – | 12,007 | Form 4 |
| 2026-02-15 | Reed John CEVP, Innovative Medicine, R&D | Shares withheld for tax F | −385 | 243.45 | 11,622 | Form 4 |
| 2026-02-15 | Reed John CEVP, Innovative Medicine, R&D | Option exercise M | +1,847 | – | 13,469 | Form 4 |
| 2026-02-15 | Reed John CEVP, Innovative Medicine, R&D | Shares withheld for tax F | −528 | 243.45 | 12,941 | Form 4 |
| 2026-02-15 | Decker Robert JVP Corporate Controller | Option exercise M | +339 | – | 23,527 | Form 4 |
| 2026-02-15 | Decker Robert JVP Corporate Controller | Shares withheld for tax F | −94 | 243.45 | 23,433 | Form 4 |
| 2026-02-15 | Decker Robert JVP Corporate Controller | Option exercise M | +344 | – | 23,777 | Form 4 |
| 2026-02-15 | Decker Robert JVP Corporate Controller | Shares withheld for tax F | −95 | 243.45 | 23,682 | Form 4 |
| 2026-02-15 | Wolk Joseph JExec VP, CFO | Option exercise M | +1,971 | – | 38,758 | Form 4 |
| 2026-02-15 | Wolk Joseph JExec VP, CFO | Shares withheld for tax F | −858 | 243.45 | 37,900 | Form 4 |
| 2026-02-15 | Wolk Joseph JExec VP, CFO | Option exercise M | +1,878 | – | 39,778 | Form 4 |
| 2026-02-15 | Wolk Joseph JExec VP, CFO | Shares withheld for tax F | −817 | 243.45 | 38,961 | Form 4 |
| 2026-02-15 | Mulholland KristenEVP, Chief HR Officer | Option exercise M | +419 | – | 19,678 | Form 4 |
| 2026-02-15 | Mulholland KristenEVP, Chief HR Officer | Shares withheld for tax F | −172 | 243.45 | 19,506 | Form 4 |
| 2026-02-15 | Mulholland KristenEVP, Chief HR Officer | Option exercise M | +575 | – | 20,081 | Form 4 |
| 2026-02-15 | Mulholland KristenEVP, Chief HR Officer | Shares withheld for tax F | −251 | 243.45 | 19,830 | Form 4 |
| 2026-02-15 | Wengel Kathryn EEVP, Chief TO and Risk Officer | Option exercise M | +606 | – | 114,288 | Form 4 |
| 2026-02-15 | Wengel Kathryn EEVP, Chief TO and Risk Officer | Shares withheld for tax F | −310 | 243.45 | 113,978 | Form 4 |
| 2026-02-15 | Wengel Kathryn EEVP, Chief TO and Risk Officer | Option exercise M | +635 | – | 114,613 | Form 4 |
| 2026-02-15 | Wengel Kathryn EEVP, Chief TO and Risk Officer | Shares withheld for tax F | −325 | 243.45 | 114,288 | Form 4 |
| 2026-02-15 | Swanson James D.EVP, CIO | Option exercise M | +492 | – | 25,512 | Form 4 |
| 2026-02-15 | Swanson James D.EVP, CIO | Shares withheld for tax F | −214 | 243.45 | 25,298 | Form 4 |
| 2026-02-15 | Swanson James D.EVP, CIO | Option exercise M | +709 | – | 26,007 | Form 4 |
| 2026-02-15 | Swanson James D.EVP, CIO | Shares withheld for tax F | −309 | 243.45 | 25,698 | Form 4 |
| 2026-02-13 | Broadhurst VanessaEVP, Global Corp Affairs | Option exercise M | +408 | – | 24,002 | Form 4 |
| 2026-02-13 | Broadhurst VanessaEVP, Global Corp Affairs | Shares withheld for tax F | −144 | 244.55 | 23,858 | Form 4 |
| 2026-02-13 | Broadhurst VanessaEVP, Global Corp Affairs | Option exercise M | +8,594 | – | 32,452 | Form 4 |
| 2026-02-13 | Broadhurst VanessaEVP, Global Corp Affairs | Shares withheld for tax F | −3,748 | 244.55 | 28,704 | Form 4 |
| 2026-02-13 | Duato JoaquinDirector, CEO and Chairman of the Board | Option exercise M | +3,469 | – | 279,436 | Form 4 |
| 2026-02-13 | Duato JoaquinDirector, CEO and Chairman of the Board | Shares withheld for tax F | −989 | 244.55 | 278,447 | Form 4 |
| 2026-02-13 | Duato JoaquinDirector, CEO and Chairman of the Board | Option exercise M | +73,054 | – | 351,501 | Form 4 |
| 2026-02-13 | Duato JoaquinDirector, CEO and Chairman of the Board | Shares withheld for tax F | −31,679 | 244.55 | 319,822 | Form 4 |
| 2026-02-13 | Schmid TimothyEVP, WW Chair, MedTech | Option exercise M | +499 | – | 22,624 | Form 4 |
| 2026-02-13 | Schmid TimothyEVP, WW Chair, MedTech | Shares withheld for tax F | −8 | 244.55 | 22,616 | Form 4 |
| 2026-02-13 | Schmid TimothyEVP, WW Chair, MedTech | Option exercise M | +4,378 | – | 26,994 | Form 4 |
| 2026-02-13 | Schmid TimothyEVP, WW Chair, MedTech | Shares withheld for tax F | −1,816 | 244.55 | 25,178 | Form 4 |
| 2026-02-13 | Taubert Jennifer LEVP, WWC. Innovative Medicine | Option exercise M | +1,302 | – | 179,315 | Form 4 |
| 2026-02-13 | Taubert Jennifer LEVP, WWC. Innovative Medicine | Shares withheld for tax F | −409 | 244.55 | 178,906 | Form 4 |
| 2026-02-13 | Taubert Jennifer LEVP, WWC. Innovative Medicine | Option exercise M | +27,412 | – | 206,318 | Form 4 |
| 2026-02-13 | Taubert Jennifer LEVP, WWC. Innovative Medicine | Shares withheld for tax F | −13,547 | 244.55 | 192,771 | Form 4 |
| 2026-02-13 | Forminard ElizabethEVP, Chief Legal Officer | Option exercise M | +651 | – | 16,199 | Form 4 |
| 2026-02-13 | Forminard ElizabethEVP, Chief Legal Officer | Shares withheld for tax F | −314 | 244.55 | 15,885 | Form 4 |
| 2026-02-13 | Forminard ElizabethEVP, Chief Legal Officer | Option exercise M | +13,706 | – | 29,591 | Form 4 |
| 2026-02-13 | Forminard ElizabethEVP, Chief Legal Officer | Shares withheld for tax F | −7,011 | 244.55 | 22,580 | Form 4 |
| 2026-02-13 | Decker Robert JVP Corporate Controller | Option exercise M | +312 | – | 21,313 | Form 4 |
| 2026-02-13 | Decker Robert JVP Corporate Controller | Shares withheld for tax F | −104 | 244.55 | 21,209 | Form 4 |
| 2026-02-13 | Decker Robert JVP Corporate Controller | Option exercise M | +2,741 | – | 23,950 | Form 4 |
| 2026-02-13 | Decker Robert JVP Corporate Controller | Shares withheld for tax F | −762 | 244.55 | 23,188 | Form 4 |
| 2026-02-13 | Wolk Joseph JExec VP, CFO | Option exercise M | +37,463 | – | 51,463 | Form 4 |
| 2026-02-13 | Wolk Joseph JExec VP, CFO | Shares withheld for tax F | −15,948 | 244.55 | 35,515 | Form 4 |
| 2026-02-13 | Wolk Joseph JExec VP, CFO | Option exercise M | +1,779 | – | 37,294 | Form 4 |
| 2026-02-13 | Wolk Joseph JExec VP, CFO | Shares withheld for tax F | −507 | 244.55 | 36,787 | Form 4 |
| 2026-02-13 | Mulholland KristenEVP, Chief HR Officer | Option exercise M | +410 | – | 16,819 | Form 4 |
| 2026-02-13 | Mulholland KristenEVP, Chief HR Officer | Shares withheld for tax F | −135 | 244.55 | 16,684 | Form 4 |
| 2026-02-13 | Mulholland KristenEVP, Chief HR Officer | Option exercise M | +3,602 | – | 20,286 | Form 4 |
| 2026-02-13 | Mulholland KristenEVP, Chief HR Officer | Shares withheld for tax F | −1,027 | 244.55 | 19,259 | Form 4 |
| 2026-02-13 | Wengel Kathryn EEVP, Chief TO and Risk Officer | Option exercise M | +651 | – | 106,607 | Form 4 |
| 2026-02-13 | Wengel Kathryn EEVP, Chief TO and Risk Officer | Shares withheld for tax F | −217 | 244.55 | 106,390 | Form 4 |
| 2026-02-13 | Wengel Kathryn EEVP, Chief TO and Risk Officer | Option exercise M | +13,706 | – | 120,096 | Form 4 |
| 2026-02-13 | Wengel Kathryn EEVP, Chief TO and Risk Officer | Shares withheld for tax F | −6,414 | 244.55 | 113,682 | Form 4 |
| 2026-02-13 | Swanson James D.EVP, CIO | Option exercise M | +447 | – | 19,298 | Form 4 |
| 2026-02-13 | Swanson James D.EVP, CIO | Shares withheld for tax F | −143 | 244.55 | 19,155 | Form 4 |
| 2026-02-13 | Swanson James D.EVP, CIO | Option exercise M | +9,412 | – | 28,567 | Form 4 |
| 2026-02-13 | Swanson James D.EVP, CIO | Shares withheld for tax F | −3,547 | 244.55 | 25,020 | Form 4 |
| 2026-02-13 | Swanson James D.EVP, CIO | Option exercise M | +19,368 | 165.89 | 44,388 | Form 4 |
| 2026-02-13 | Swanson James D.EVP, CIO | Option exercise M | +22,191 | 162.75 | 47,211 | Form 4 |
| 2026-02-06 | Schmid TimothyEVP, WW Chair, MedTech | Option exercise M | +15,571 | 101.87 | 32,460 | Form 4 |
| 2026-02-06 | Schmid TimothyEVP, WW Chair, MedTech | Shares withheld for tax F | −10,335 | 239.99 | 22,125 | Form 4 |
| 2026-02-06 | Wengel Kathryn EEVP, Chief TO and Risk Officer | Option exercise M | +38,945 | 101.87 | 133,226 | Form 4 |
| 2026-02-06 | Wengel Kathryn EEVP, Chief TO and Risk Officer | Shares withheld for tax F | −27,270 | 239.99 | 105,956 | Form 4 |
| 2026-02-06 | Mulholland KristenEVP, Chief HR Officer | Option exercise M | +5,625 | 101.87 | 19,744 | Form 4 |
| 2026-02-06 | Mulholland KristenEVP, Chief HR Officer | Shares withheld for tax F | −3,335 | 239.99 | 16,409 | Form 4 |
| 2026-02-05 | Forminard ElizabethEVP, Chief Legal Officer | Option exercise M | +8,921 | 129.51 | 21,774 | Form 4 |
| 2026-02-05 | Forminard ElizabethEVP, Chief Legal Officer | Shares withheld for tax F | −6,226 | 237.90 | 15,548 | Form 4 |
| 2025-10-17 | Reed John CEVP, Innovative Medicine, R&D | Option exercise M | +21,721 | 157.92 | 32,379 | Form 4 |
| 2025-09-04 | Taubert Jennifer LEVP, WWC. Innovative Medicine | Option exercise M | +56,471 | 101.87 | 234,484 | Form 4 |
| 2025-08-29 | Forminard ElizabethExecutive VP, General Counsel | Option exercise M | +11,521 | 115.67 | 22,423 | Form 4 |
| 2025-08-29 | Forminard ElizabethExecutive VP, General Counsel | Shares withheld for tax F | −9,570 | 177.20 | 12,853 | Form 4 |
| 2025-08-22 | Duato JoaquinDirector, CEO and Chairman of the Board | Option exercise M | +125,824 | 101.87 | 401,791 | Form 4 |
| 2025-08-15 | Wolk Joseph JExec VP, CFO | Option exercise M | +16,820 | 101.87 | 30,820 | Form 4 |
| 2025-05-01 | Reed John CEVP, Innovative Medicine, R&D | Option exercise M | +25,255 | – | 40,797 | Form 4 |
| 2025-05-01 | Reed John CEVP, Innovative Medicine, R&D | Shares withheld for tax F | −11,002 | 156.31 | 29,795 | Form 4 |
| 2025-03-18 | Duato JoaquinDirector, CEO and Chairman of the Board | Gift G | −130,852 | – | 275,967 | Form 4 |
| 2025-03-18 | Duato JoaquinDirector, CEO and Chairman of the Board | Gift G | +130,852 | – | 130,852 | Form 4 |
| 2025-02-25 | Decker Robert JVP Corporate Controller | Option exercise M | +6,999 | 101.87 | 28,000 | Form 4 |
| 2025-02-18 | Broadhurst VanessaEVP, Global Corp Affairs | Shares withheld for tax F | −158 | 156.15 | 21,681 | Form 4 |
| 2025-02-18 | Decker Robert JVP Corporate Controller | Shares withheld for tax F | −94 | 156.15 | 20,022 | Form 4 |
| 2025-02-18 | Duato JoaquinDirector, CEO and Chairman of the Board | Shares withheld for tax F | −1,602 | 156.15 | 395,923 | Form 4 |
| 2025-02-18 | Forminard ElizabethExecutive VP, General Counsel | Shares withheld for tax F | −307 | 156.15 | 10,014 | Form 4 |
| 2025-02-18 | Mulholland KristenEVP, Chief HR Officer | Shares withheld for tax F | −120 | 156.15 | 12,975 | Form 4 |
| 2025-02-18 | Swanson James D.EVP, CIO | Shares withheld for tax F | −141 | 156.15 | 16,621 | Form 4 |
| 2025-02-18 | Taubert Jennifer LEVP, WWC. Innovative Medicine | Shares withheld for tax F | −651 | 156.15 | 170,459 | Form 4 |
| 2025-02-18 | Reed John CEVP, Innovative Medicine, R&D | Shares withheld for tax F | −385 | 156.15 | 15,542 | Form 4 |
| 2025-02-18 | Wolk Joseph JExec VP, CFO | Shares withheld for tax F | −768 | 156.15 | 5,345 | Form 4 |
| 2025-02-18 | Wengel Kathryn EEVP, Chief TO and Risk Officer | Shares withheld for tax F | −200 | 156.15 | 90,837 | Form 4 |
| 2025-02-15 | Broadhurst VanessaEVP, Global Corp Affairs | Option exercise M | +492 | – | 21,839 | Form 4 |
| 2025-02-15 | Decker Robert JVP Corporate Controller | Option exercise M | +339 | – | 20,116 | Form 4 |
| 2025-02-15 | Duato JoaquinDirector, CEO and Chairman of the Board | Option exercise M | +3,682 | – | 397,525 | Form 4 |
| 2025-02-15 | Forminard ElizabethExecutive VP, General Counsel | Option exercise M | +961 | – | 10,321 | Form 4 |
| 2025-02-15 | Mulholland KristenEVP, Chief HR Officer | Option exercise M | +419 | – | 13,095 | Form 4 |
| 2025-02-15 | Swanson James D.EVP, CIO | Option exercise M | +492 | – | 16,762 | Form 4 |
| 2025-02-15 | Taubert Jennifer LEVP, WWC. Innovative Medicine | Option exercise M | +1,594 | – | 171,110 | Form 4 |
| 2025-02-15 | Reed John CEVP, Innovative Medicine, R&D | Option exercise M | +1,350 | – | 15,927 | Form 4 |
| 2025-02-15 | Wolk Joseph JExec VP, CFO | Option exercise M | +1,971 | – | 6,113 | Form 4 |
| 2025-02-15 | Wengel Kathryn EEVP, Chief TO and Risk Officer | Option exercise M | +607 | – | 91,037 | Form 4 |
| 2025-02-15 | Schmid TimothyEVP, WW Chair, MedTech | Option exercise M | +1,029 | – | 15,501 | Form 4 |
| 2025-02-14 | Broadhurst VanessaEVP, Global Corp Affairs | Shares withheld for tax F | −151 | 155.26 | 20,091 | Form 4 |
| 2025-02-14 | Broadhurst VanessaEVP, Global Corp Affairs | Option exercise M | +1,830 | – | 21,921 | Form 4 |
| 2025-02-14 | Broadhurst VanessaEVP, Global Corp Affairs | Shares withheld for tax F | −574 | 156.71 | 21,347 | Form 4 |
| 2025-02-14 | Broadhurst VanessaEVP, Global Corp Affairs | Option exercise M | +2,910 | – | 24,591 | Form 4 |
| 2025-02-14 | Broadhurst VanessaEVP, Global Corp Affairs | Shares withheld for tax F | −997 | 156.71 | 23,594 | Form 4 |
| 2025-02-14 | Decker Robert JVP Corporate Controller | Shares withheld for tax F | −104 | 155.26 | 19,181 | Form 4 |
| 2025-02-14 | Decker Robert JVP Corporate Controller | Option exercise M | +850 | – | 20,031 | Form 4 |
| 2025-02-14 | Decker Robert JVP Corporate Controller | Shares withheld for tax F | −254 | 156.71 | 19,777 | Form 4 |
| 2025-02-14 | Decker Robert JVP Corporate Controller | Option exercise M | +1,351 | – | 21,373 | Form 4 |
| 2025-02-14 | Decker Robert JVP Corporate Controller | Shares withheld for tax F | −372 | 156.71 | 21,001 | Form 4 |
| 2025-02-14 | Duato JoaquinDirector, CEO and Chairman of the Board | Shares withheld for tax F | −1,510 | 155.26 | 390,988 | Form 4 |
| 2025-02-14 | Duato JoaquinDirector, CEO and Chairman of the Board | Option exercise M | +5,053 | – | 396,041 | Form 4 |
| 2025-02-14 | Duato JoaquinDirector, CEO and Chairman of the Board | Shares withheld for tax F | −2,198 | 156.71 | 393,843 | Form 4 |
| 2025-02-14 | Duato JoaquinDirector, CEO and Chairman of the Board | Option exercise M | +19,282 | – | 415,205 | Form 4 |
| 2025-02-14 | Duato JoaquinDirector, CEO and Chairman of the Board | Shares withheld for tax F | −8,386 | 156.71 | 406,819 | Form 4 |
| 2025-02-14 | Forminard ElizabethExecutive VP, General Counsel | Shares withheld for tax F | −215 | 155.26 | 8,776 | Form 4 |
| 2025-02-14 | Forminard ElizabethExecutive VP, General Counsel | Option exercise M | +851 | – | 9,627 | Form 4 |
| 2025-02-14 | Forminard ElizabethExecutive VP, General Counsel | Shares withheld for tax F | −267 | 156.71 | 9,360 | Form 4 |
| 2025-02-14 | Forminard ElizabethExecutive VP, General Counsel | Option exercise M | +1,352 | – | 11,366 | Form 4 |
| 2025-02-14 | Forminard ElizabethExecutive VP, General Counsel | Shares withheld for tax F | −464 | 156.71 | 10,902 | Form 4 |
| 2025-02-14 | Mulholland KristenEVP, Chief HR Officer | Shares withheld for tax F | −141 | 155.26 | 11,959 | Form 4 |
| 2025-02-14 | Mulholland KristenEVP, Chief HR Officer | Option exercise M | +1,007 | – | 12,966 | Form 4 |
| 2025-02-14 | Mulholland KristenEVP, Chief HR Officer | Shares withheld for tax F | −290 | 156.71 | 12,676 | Form 4 |
| 2025-02-14 | Mulholland KristenEVP, Chief HR Officer | Option exercise M | +1,601 | – | 14,576 | Form 4 |
| 2025-02-14 | Mulholland KristenEVP, Chief HR Officer | Shares withheld for tax F | −457 | 156.71 | 14,119 | Form 4 |
| 2025-02-14 | Swanson James D.EVP, CIO | Shares withheld for tax F | −152 | 155.26 | 14,867 | Form 4 |
| 2025-02-14 | Swanson James D.EVP, CIO | Option exercise M | +1,961 | – | 16,828 | Form 4 |
| 2025-02-14 | Swanson James D.EVP, CIO | Shares withheld for tax F | −558 | 156.71 | 16,270 | Form 4 |
| 2025-02-14 | Swanson James D.EVP, CIO | Option exercise M | +3,118 | – | 19,739 | Form 4 |
| 2025-02-14 | Swanson James D.EVP, CIO | Shares withheld for tax F | −889 | 156.71 | 18,850 | Form 4 |
| 2025-02-14 | Taubert Jennifer LEVP, WWC. Innovative Medicine | Shares withheld for tax F | −410 | 155.26 | 166,811 | Form 4 |
| 2025-02-14 | Taubert Jennifer LEVP, WWC. Innovative Medicine | Option exercise M | +4,053 | – | 170,864 | Form 4 |
| 2025-02-14 | Taubert Jennifer LEVP, WWC. Innovative Medicine | Shares withheld for tax F | −1,348 | 156.71 | 169,516 | Form 4 |
| 2025-02-14 | Taubert Jennifer LEVP, WWC. Innovative Medicine | Option exercise M | +15,465 | – | 185,924 | Form 4 |
| 2025-02-14 | Taubert Jennifer LEVP, WWC. Innovative Medicine | Shares withheld for tax F | −7,911 | 156.71 | 178,013 | Form 4 |
| 2025-02-14 | Wolk Joseph JExec VP, CFO | Shares withheld for tax F | −507 | 155.26 | 1,272 | Form 4 |
| 2025-02-14 | Wolk Joseph JExec VP, CFO | Option exercise M | +4,014 | – | 5,286 | Form 4 |
| 2025-02-14 | Wolk Joseph JExec VP, CFO | Shares withheld for tax F | −1,144 | 156.71 | 4,142 | Form 4 |
| 2025-02-14 | Wolk Joseph JExec VP, CFO | Option exercise M | +15,316 | – | 20,661 | Form 4 |
| 2025-02-14 | Wolk Joseph JExec VP, CFO | Shares withheld for tax F | −6,661 | 156.71 | 14,000 | Form 4 |
| 2025-02-14 | Wengel Kathryn EEVP, Chief TO and Risk Officer | Shares withheld for tax F | −223 | 155.26 | 89,380 | Form 4 |
| 2025-02-14 | Wengel Kathryn EEVP, Chief TO and Risk Officer | Option exercise M | +1,530 | – | 90,910 | Form 4 |
| 2025-02-14 | Wengel Kathryn EEVP, Chief TO and Risk Officer | Shares withheld for tax F | −480 | 156.71 | 90,430 | Form 4 |
| 2025-02-14 | Wengel Kathryn EEVP, Chief TO and Risk Officer | Option exercise M | +5,837 | – | 96,674 | Form 4 |
| 2025-02-14 | Wengel Kathryn EEVP, Chief TO and Risk Officer | Shares withheld for tax F | −2,393 | 156.71 | 94,281 | Form 4 |
| 2025-02-14 | Schmid TimothyEVP, WW Chair, MedTech | Shares withheld for tax F | −193 | 155.26 | 13,346 | Form 4 |
| 2025-02-14 | Schmid TimothyEVP, WW Chair, MedTech | Option exercise M | +1,765 | – | 15,111 | Form 4 |
| 2025-02-14 | Schmid TimothyEVP, WW Chair, MedTech | Shares withheld for tax F | −639 | 156.71 | 14,472 | Form 4 |
| 2025-02-14 | Schmid TimothyEVP, WW Chair, MedTech | Option exercise M | +2,806 | – | 17,904 | Form 4 |
| 2025-02-14 | Schmid TimothyEVP, WW Chair, MedTech | Shares withheld for tax F | −1,015 | 156.71 | 16,889 | Form 4 |
| 2025-02-13 | Broadhurst VanessaEVP, Global Corp Affairs | Option exercise M | +408 | – | 20,242 | Form 4 |
| 2025-02-13 | Decker Robert JVP Corporate Controller | Option exercise M | +312 | – | 19,285 | Form 4 |
| 2025-02-13 | Duato JoaquinDirector, CEO and Chairman of the Board | Option exercise M | +3,470 | – | 392,498 | Form 4 |
| 2025-02-13 | Forminard ElizabethExecutive VP, General Counsel | Option exercise M | +651 | – | 8,991 | Form 4 |
| 2025-02-13 | Mulholland KristenEVP, Chief HR Officer | Option exercise M | +411 | – | 12,100 | Form 4 |
How to read it
- Buy, sale
- Code P and S on the form: shares bought or sold in the market, at the market price. The other codes are mostly pay (a grant, an option exercised) or tax (shares the company withheld), and say little about what the insider thinks of the price.
- Plan
- A sale or purchase under a Rule 10b5-1 plan, set up in advance and running on its own schedule. Since April 2023 the form has a box for it. Much executive selling is planned and says more about diversifying than about the company.
- Holds after
- The shares the insider still held after the trade, in the form the trade was in (directly, or indirectly through a trust or a fund).
- Value
- Shares times the price the form reports, which is often an average over several fills on the day.
Read from the SEC's own quarterly data sets of Forms 3, 4 and 5, and from each day's filings since the last one. A correcting amendment replaces the lines it restates. Every row links to its filing. None of this is advice: insiders sell for many reasons, and buy for fewer.